Axitinib Impurity 47(CAS: 20054-45-9)

Axitinib Impurity 47 (CAS: 20054-45-9) is subject to regulatory guidelines such as the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), REACH regulations in the European Union, and FDA/EPA requirements for pharmaceutical and chemical substances. Compliance with these guidelines ensures safety and proper handling in manufacturing and distribution.

In synthesis, alternatives to Axitinib Impurity 47 (CAS: 20054-45-9) include using isomers, analogs, and other substitute reagents. For instance, using isomers with similar properties or alternative impurities can provide a viable synthesis route. These alternatives should be carefully evaluated for their effectiveness and safety.

The market and research trend for Axitinib Impurity 47 (CAS: 20054-45-9) reflects increasing interest in pharmaceuticals and targeted therapy research. Trends indicate a focus on improving drug purity and reducing impurity levels, leading to advancements in purification techniques and analytical methods.

Waste containing Axitinib Impurity 47 (CAS: 20054-45-9) should be collected and disposed of in accordance with local environmental regulations. Proper waste handling includes incineration or professional waste disposal services. Ensure compliance with environmental protection measures to minimize ecological impact and ensure safety during disposal processes.